Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

Posters will be made available on the Kineta website following presentations at the conference. KEYTRUDA ® is a registered trademark ... and a preclinical monoclonal antibody targeting CD27. For more ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

Thousands of Veterans have learned they're eligible for healthcare, food and housing benefits through enhanced interoperability between VA software and Epic. Caregivers using Epic's software can ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

To learn about other mild side effects, talk with your doctor or pharmacist, or read Keytruda’s prescribing information. Mild side effects of Keytruda that have been reported include ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...